A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 4, 2005, Pages 393-398

  Shamseddine, Ali ^a   Khalifeh, Mohammed ^a   Chehal, Aref ^a   Saliba, Teddy ^a   Mourad, Yasser Abou ^a   Taher, Ali ^a   Jalloul, Rahif ^b   Bitar, Nizar ^c   Dandashi, Azzam ^d   Abbas, Jaber ^a   Geara, Fady B ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b MAKASSED GENERAL HOSPITAL   (Lebanon)

^c Sahel General Hospital   (Lebanon)

^d Islamic Hospital Tripoli   (Lebanon)

Author keywords

Advanced breast cancer; Cisplatinum; Vinorelbine

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; GEMCITABINE; METOCLOPRAMIDE; NAVELBINE; PACLITAXEL; SEROTONIN ANTAGONIST; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; BONE MARROW TOXICITY; BREAST CARCINOMA; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; REVIEW; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, LOBULAR; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 23244462235     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000145335.39398.ee     Document Type: Review

References (31)

1. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993;11:1245-1252.
2. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994;5:854-857.
3. Weber BL, Vogel C, Jones S, et al. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995;13:2722-2730.
4. Bruno S, Puerto VL, Mickiewicz E, et al. Phase II trial of weekly i. v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol. 1995;18: 392-396.
5. Escudero P, Bueso P, Mayordomo JI, et al. Docetaxel plus vinorelbine is an active combination for patients with anthracycline-refractory metastatic breast cancer. Results of a phase II trial. Proc Am Soc Clin Oncol. 1998;17:529.
6. Fumoleau P, Fety R, Delecroix V, et al. Docetaxel combined with vinorelbine: phase I results and new study designs. Oncology. 1997;11: 29-31.
7. Botto HG, Botto ME, Otegui ML, et al. Taxotere vs vinorelbine and Taxol in patients with metastatic breast anthracycline resistant. Proc Am Soc Clin Oncol. 1998;17:498.
8. Romero Acuna L, Langhi M, Perez J, et al. Vinorelbine and paclitaxel as first line chemotherapy in metastatic breast cancer. J Clin Oncol. 1999;17:74-81.
9. Kourousis C, Kakolyris S, Androulakis N, et al. Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. Am J Clin Oncol. 1998;21:226-232.
10. Chadjaa M, Izzo J, May-Levin F, et al. Preliminary data on 4′ epiadriamycin-vinorelbine: a new active combination in advanced breast cancer. Proc Am Soc Clin Oncol. 1993;12:88(abstr 152).
11. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001;19:2722-2730.
12. Sledge GW Jr, Loehrer PJ Sr, Roth BJ, et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 1988;6:1811-1814.
13. Kolaric K, Roth A. Phase II trial of cis-dichlorodiammine platinum (Cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1983;11: 108-112.
14. Henderson IC, Garber JE, Breitneyer JB. Comprehensive management of disseminated breast cancer. Cancer. 1990;66:1439-1448.
15. Llombart-Cussac A, Spielmann M, Dohollou N, et al. Cisplatinum-taxotere phase I/II trial in patients with anthracycline-resistant breast cancer (ENG). Proc Am Soc Clin Oncol 1997;16:629.
16. Bernard A, Antoine EC, Gozy M, et al. Docetaxel and cisplatin in anthracycline-pretreated advanced breast cancer: results of a phase II pilot study. Proc Am Soc Clin Oncol. 1998;17:491.
17. Antoine EC, Gozy M, Benhammouda A, et al. A phase II study of docetaxel and cisplatin in anthracycline-pretreated advanced breast cancer: preliminary results (ENG). Proc 7th International Congress on Anticancer Treatment. Paris, February 3-6, 1997.
18. Nagourney RA, Link JS, Blitzer JB, et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer. J Clin Oncol. 2000;18:2245-2249.
19. Shamseddine AI, Taher A, Dabaja B, et al. Combination cisplatin-vinorelbine for relapsed and chemotherapy-pretreated metastatic breast cancer. Am J Clin Oncol. 1999;22:298-302.
20. Ray-Coquard I, Biron P, Bachelot T, et al. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. Cancer. 1998;82:134-40.
21. Gunel N, Akcali Z, Yamac D, et al. Cisplatin plus vinorelbine as a salvage regimen in refractory breast cancer. Tumori. 2000;86:283-285.
22. Sparano JA, O'Neill A, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol. 2000;18:2369-2377.
23. Nistico C, Garufi C, Barni S, et al. Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: a high-activity, dose-dense weekly regimen for advanced breast cancer. Ann Oncol. 1999;10:937-942.
24. Mustacchi G, Muggia M, Milani S, et al. A phase 11 study of cisplatin and vinorelbine in patients with metastatic breast cancer. Ann Oncol. 2002;13:1730-1736.
25. Cros S, Wright M, Morimoto M, et al. Experimental activity of navelbine. Semin Oncol. 1989;16:15-20.
26. Hochster H, Wasserheit C, Siddiqui N, et al. Vinorelbine/cisplatin therapy of locally advanced and metastatic breast cancer: an active regimen [Abstr 606]. Proc Am Soc Clin Oncol. 1997;16:173a.
27. Gardin G, Rosso R, Campora E, et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer. 1995;31A:1428-1433.
28. Smith IE, Walsh G, Jones A, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995;13:424-429.
29. Klastersky JO, Schulier G, Bureau P, et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small cell lung cancer. J Clin Oncol. 1989;7:1087-1092.
30. Vassilomanolakis M, Koumakis G, Barbounis V, et al. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines. Ann Oncol. 2000;11:1155-1160.
31. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-1466.